SG11201908077XA - Methods of use of soluble cd24 for treating systemic lupus erythematosus - Google Patents

Methods of use of soluble cd24 for treating systemic lupus erythematosus

Info

Publication number
SG11201908077XA
SG11201908077XA SG11201908077XA SG11201908077XA SG11201908077XA SG 11201908077X A SG11201908077X A SG 11201908077XA SG 11201908077X A SG11201908077X A SG 11201908077XA SG 11201908077X A SG11201908077X A SG 11201908077XA SG 11201908077X A SG11201908077X A SG 11201908077XA
Authority
SG
Singapore
Prior art keywords
international
street
pct
lupus erythematosus
systemic lupus
Prior art date
Application number
SG11201908077XA
Inventor
Yang Liu
Pan Zheng
Martin Devenport
Original Assignee
Oncoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoimmune Inc filed Critical Oncoimmune Inc
Publication of SG11201908077XA publication Critical patent/SG11201908077XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 13 September 2018 (13.09.2018) WIPO I PCT 0111111010 0111 °nolo ominiololommom oimIE (10) International Publication Number WO 2018/165204 Al (51) International Patent Classification: A61K 38/17 (2006.01) CO7K 14/705 (2006.01) A61K 39/00 (2006.01) (21) International Application Number: PCT/US2018/021214 (22) International Filing Date: 06 March 2018 (06.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/468,049 07 March 2017 (07.03.2017) US (71) Applicant: ONCOIMMUNE, INC. [US/US]; 9430 Key West Avenue, Suite 113, Rockville, Maryland 20850 (US). (72) Inventors: LIU, Yang; 502 E Street NE, Washington, Dis- trict of Columbia 20002 (US). ZHENG, Pan; 502 E Street NE, Washington, District of Columbia 20002 (US). DE- VENPORT, Martin; 607 Gatestone Street, Gaithersburg, Maryland 20878 (US). (74) Agent: GALANT, Ron et al.; Polsinelli PC, 150 N. River- side Plaza, Suite 3000, Chicago, Illinois 60606 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) (54) Title: METHODS OF USE OF SOLUBLE CD24 FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS FIG. 1A MGRAMVARLGLGLLLLALLL PTQ I Y S SETTTGTS SNSSQSTSNSGLAP NPTNATTKPKSCDKTHTCPPCPAPELLGGPSVFLEPPKPKDILMI SRT PEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVS VLTVLHQDWLNGKEYKCKVSNKAL PAP I EKT I SKAKGQPREPQVYTLP P SRDELTKNQVSLTCLVKGFYP SDIAVEWESNGQPENNYKTT PPVLDS DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 1-1 O C (57) : The present invention relates to the use of a CD24 protein for treating Systemic Lupus Erythematosus (Lupus, SLE).
SG11201908077XA 2017-03-07 2018-03-06 Methods of use of soluble cd24 for treating systemic lupus erythematosus SG11201908077XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762468049P 2017-03-07 2017-03-07
PCT/US2018/021214 WO2018165204A1 (en) 2017-03-07 2018-03-06 Methods of use of soluble cd24 for treating systemic lupus erythematosus

Publications (1)

Publication Number Publication Date
SG11201908077XA true SG11201908077XA (en) 2019-09-27

Family

ID=63449062

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201908077XA SG11201908077XA (en) 2017-03-07 2018-03-06 Methods of use of soluble cd24 for treating systemic lupus erythematosus

Country Status (9)

Country Link
US (1) US11571461B2 (en)
EP (1) EP3592375A4 (en)
JP (1) JP2020510020A (en)
KR (1) KR20190126801A (en)
CN (1) CN110461353A (en)
AU (1) AU2018231166A1 (en)
CA (1) CA3055294A1 (en)
SG (1) SG11201908077XA (en)
WO (1) WO2018165204A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4103218A4 (en) * 2020-02-10 2024-05-01 Oncoimmune Inc Methods of use of soluble cd24 for treating sars-cov-2 infection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1267909T3 (en) * 2000-03-29 2010-11-08 Univ Ohio State Res Found Methods for blocking tissue destruction by autoreactive T cells
US20030106084A1 (en) * 2000-03-29 2003-06-05 Yang Liu Methods of blocking tissue destruction by autoreactive T cells
US20130231464A1 (en) * 2010-04-28 2013-09-05 Oncolmmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis
PL3260128T3 (en) * 2010-04-28 2021-02-08 Oncoimmune, Inc. Medical use of soluble cd24
WO2016073704A1 (en) 2014-11-06 2016-05-12 Children's Research Institute, Children's National Medical Center Immunotherapeutics for cancer and autoimmune diseases
CN107531772B (en) * 2015-05-07 2021-09-21 肿瘤免疫股份有限公司 Use of CD24 for reducing low density lipoprotein cholesterol levels

Also Published As

Publication number Publication date
US11571461B2 (en) 2023-02-07
CA3055294A1 (en) 2018-09-13
CN110461353A (en) 2019-11-15
WO2018165204A1 (en) 2018-09-13
KR20190126801A (en) 2019-11-12
US20220125874A1 (en) 2022-04-28
EP3592375A1 (en) 2020-01-15
JP2020510020A (en) 2020-04-02
AU2018231166A1 (en) 2019-09-26
EP3592375A4 (en) 2021-01-20

Similar Documents

Publication Publication Date Title
SG11201907770YA (en) Systems and methods for determining a parking region of vehicles
SG11201809913PA (en) Methods for detecting target nucleic acids in a sample
SG11202000105QA (en) Anti-cd166 antibodies and uses thereof
SG11201804086VA (en) Methods and compositions for nucleic acid analysis
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201909454QA (en) Container-based virtual camera rotation
SG11201804556YA (en) System, method, and device for generating a geographic area heat map
SG11201808797XA (en) T cell receptors
SG11201900746RA (en) Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
SG11201807474SA (en) Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies
SG11201811659PA (en) Systems and methods for determining an estimated time of arrival
SG11201907023UA (en) Method of reducing neutropenia
SG11201909728XA (en) Constructs specifically recognizing glypican 3 and uses thereof
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201807720TA (en) Methods and systems for determining antibiotic susceptibility
SG11201809473QA (en) Humanized anti-basigin antibodies and the use thereof
SG11201811690TA (en) Systems and methods for cheat examination
SG11201803998PA (en) Systems and methods for updating sequence of services
SG11201900744SA (en) Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
SG11201810989VA (en) Systems and methods for route planning
SG11201906961UA (en) Polypeptide variants and uses thereof
SG11201907490XA (en) Non-human animal models of retinoschisis
SG11201907208XA (en) Radiolabeled anti-lag3 antibodies for immuno-pet imaging
SG11201910195WA (en) Methods for trapping and barcoding discrete biological units in hydrogel
SG11201906682YA (en) Glucagon receptor binding proteins and methods of use thereof